Jorge Soler Iglesias
Payments from drug & device makers
Across 293 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$789
- AbbVie$527
- GSK$495
- AstraZeneca$428
- Bayer$363
- Dexcom, Inc.$341
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $789 |
| AbbVie | 34 | $527 |
| GSK | 31 | $495 |
| AstraZeneca | 21 | $428 |
| Bayer | 23 | $363 |
| Dexcom, Inc. | 18 | $341 |
| Lilly USA, LLC | 14 | $290 |
| Merck | 13 | $250 |
| Amgen | 11 | $215 |
| Pfizer | 11 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $171 |
| Johnson & Johnson | 11 | $157 |
| Abbott | 7 | $127 |
| La Jolla Pharmaceutical Company | 1 | $113 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| SK Life Science, Inc. | 4 | $92 |
| Baxter Healthcare | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Viatris Specialty LLC | 3 | $69 |
| Biohaven Pharmaceuticals, Inc. | 4 | $68 |
| Mylan Specialty L.p. | 2 | $56 |
| Radius Health, Inc. | 3 | $49 |
| Boehringer Ingelheim | 3 | $43 |
| Novartis | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Phadia US Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Boston Scientific | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Biogen | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Sarepta Therapeutics, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,410 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $98,717 |
| JardianceEmpagliflozin | 72 | $73,834 |
| JanuviaSitagliptin Phosphate | 36 | $38,475 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $34,966 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $34,432 |
| EliquisApixaban | 41 | $32,986 |
| MounjaroTirzepatide | 14 | $17,121 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $10,433 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $6,632 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $2,957 |
| Fluticasone Propionate HfaFluticasone Propionate | 16 | $2,939 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 121 | $2,844 |
| PremarinEstrogens, Conjugated | 14 | $2,568 |
| Gabapentin | 127 | $2,407 |
| Diclofenac Sodium | 27 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $789 | $98,71786 claims |
| Boehringer IngelheimJardiance | $43 | $73,83472 claims |
| MerckJanuvia | $250 | $38,47536 claims |
| PfizerEliquis, Premarin | $173 | $35,55455 claims |
| GSKTrelegy Ellipta | $495 | $34,96643 claims |
| Lilly USA, LLCMounjaro | $290 | $17,12114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.